Skip to main content

Use avidity to identify the best NK cell with optimal response

Part of: CAR-NK / NK cells

Use avidity to identify the best NK cell with optimal response

Cell avidity depict stronger binding of INKmune-primed NK cells that eradicate residual disease

Cell avidity measurements compared NK cell binding (IL-2, IL-15, and INKmune-primed) to NK-resistant SKOV3 cancer cells. INKmune-primed NK cells showed superior avidity, forming stronger immune synapses for effective cancer cell killing (Figure 1).

Unlike IL-2/IL-15 activation with off-target toxicities, INKmune enables precise NK cell activation without harming healthy tissues. Additionally, INKmune-primed NK cells resist exhaustion, overcoming inhibition in the tumor microenvironment. Cell avidity measurements demonstrate INKmune’s efficacy in accelerating immunotherapy development by predicting in vivo and clinical success.

Download webinar
Figure 1. Cell avidity between resting-, INKmune-primed-, IL-2 primed-, IL-15 primed- NK cells and NK-resistant SKOV3 tumor cells.The avidity curves show the percentage of target-bound NK cells upon increasing acoustic forces. rForce indicates relative force.

Prof. Mark Lowdell

CSO and Founder at Inmune Bio
University College London

“Cell avidity measurements with the z-Movi Cell Avidity Analyzer provide key information that can accelerate immunotherapy development by accurately predicting in vivo and clinical efficacy

Cell avidity revealed as the best and earliest predictor for in vivo tumor control for CAR-NK cells

Recent work using cell avidity measurements by the Gottschalk lab at St. Jude Children’s Research Hospital (published in Nature Biotechnology) sought to tune CAR synapses in NK cells by adding an intracellular scaffolding protein binding site to the CAR called the PDZ binding motif.

PDZ specifically binds Scribble resulting in additional scaffolding and crosslinking to enhance synapse formation resulting in increased avidity and in vivo efficacy

Download webinar
Peter Chockley

Dr. Peter Chockley

St. Jude Children’s Research hospital

“Most influential were the avidity measurements that directly interrogated the strength of synapse”

Cell Avidity predicts the most efficacious NK cell donor

In addition to autologous cellular therapy, allogeneic strategies may facilitate an off-the-shelf solution, including NK cells as a prime example.

In this assay, researchers from Glycostem Therapeutics B.V. compared cell avidity data with cell killing by evaluating NK functionalities from two different donors (donor 1 and donor 2).

Data courtesy of Glycosystem Therapeutics B.V.

Our solutions

Cell avidity as a service

Cell Avidity analysis can be performed at high throughput using our services platform, enabling the screening of hundreds of Cell Engagers to rapidly find the most potent Cell Engager for in vivo testing. 

Dr. Rogier Reijmers
Principal Scientist at LUMICKS

Download the brochure to learn more

Join our mailing list

I would like to receive exclusive news about the latest product developments, dynamic single-molecule and immuno-oncology events and breakthrough science. I can revoke my consent at any time.

By submitting the form you agree to LUMICKS' privacy policy.

Close Menu

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:


Download our Cell Therapy (CAR-T, TCR, NK) applications deck